Milestone Pharmaceuticals (MIST) has disclosed a new risk, in the Regulation category.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Milestone Pharmaceuticals faces heightened exposure to operational delays because disruptions at the FDA, SEC, or comparable foreign regulators can slow review and approval timelines for its product candidates. Political gridlock, agency funding shortages, staffing gaps, and government shutdowns may all impair these authorities’ ability to perform core functions on which Milestone’s development and commercialization plans depend, potentially causing material adverse business impacts.
The average MIST stock price target is $8.00, implying 488.24% upside potential.
To learn more about Milestone Pharmaceuticals’ risk factors, click here.